Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Datamonitor Healthcare Reports | Commercial and Pipeline Insight - Hepatitis B

Commercial and Pipeline Insight - Hepatitis B

"IntroductionFuelled by an increasing disease awareness, the growing use of new, expensive drugs as well as combination therapy, the HBV drugs market, sized at $431m in 2006 across the seven major markets, will nearly triple in size by 2016. Rapid growth until 2011 will slow down in the following years as a result of genericization and the beginning impact of routine HBV vaccination.ScopeIn-depth analysis of the current hepatitis B market situation across the major Western markets Thorough assessment of underlying commercial and clinical influencers shaping the hepatitis B market Detailed sales forecasts for key hepatitis B drug classes, molecules and brands in each of the seven major markets In-depth discussion of novel hepatitis B pipeline candidates and assessment of their future potentialHighlightsDue to their good safety profile and increasing efficacy, antivirals will expand their lead as the dominant drug class for HBV treatment. Particularly Bristol-Myer Squibb's Baraclude (entecavir) will experience a rapid uptake. Interferons will benefit from increased diagnosis rates and combination therapy, but their overall use will remain limited. Launch of Gilead's tenofovir, already marketed for HIV and currently in Phase III trials for HBV, is expected for 2008. Driven by its excellent efficacy, safety and resistance profile, tenofovir will replace entecavir as the market leader by 2013, reaching peak sales of up to $400m across the 7MM. HBV vaccination is becoming increasingly established across the 7MM, but its impact is mitigated by immigration from areas of high disease prevalence. Merck & Co and GSK currently dominate this market. Therapeutic vaccines offer hope for a cure, but are a long way from approval.Reasons to PurchaseReview the clinical and commercial factors driving new product decisions in hepatitis B, and the opportunities and threats facing the market Gain insight through a detailed sales forecast and a thorough analysis of marketed and pipeline products Understand where concerns, unmet needs and future opportunities lie by learning about the views of key hepatitis B opinion leaders."

31-Oct-07 Format: PDF & SlidePack & DataPack Pages: 241
Table of Contents
Price: $15,200.00 / €10,168.80

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions